Key regions: Japan, India, Italy, Brazil, South Korea
The Anti-Hypertensive Drugs market in Equatorial Guinea has been experiencing a steady growth in recent years.
Customer preferences: As in many other countries, hypertension is a major health concern in Equatorial Guinea, with a significant proportion of the population suffering from the condition. This has led to an increasing demand for Anti-Hypertensive Drugs in the country. Patients in Equatorial Guinea generally prefer generic drugs due to their affordability, and this trend is reflected in the Anti-Hypertensive Drugs market as well.
Trends in the market: The Anti-Hypertensive Drugs market in Equatorial Guinea has been growing at a steady pace in recent years. This growth can be attributed to several factors, including an increase in the prevalence of hypertension in the country, rising healthcare expenditure, and an increase in the availability of generic drugs. The market is dominated by a few major players, who have a significant market share. However, there is also a growing presence of smaller players in the market, who are catering to the demand for generic drugs.
Local special circumstances: Equatorial Guinea is a small country with a relatively small population. The healthcare system in the country is still developing, and there are significant gaps in healthcare infrastructure and services. This has led to a high burden of disease in the country, including hypertension. However, the government has been taking steps to improve healthcare services in the country, which is expected to drive growth in the Anti-Hypertensive Drugs market as well.
Underlying macroeconomic factors: Equatorial Guinea is a middle-income country with a relatively stable economy. The country is heavily dependent on its oil and gas sector, which accounts for a significant proportion of its GDP. However, the government has been taking steps to diversify the economy and reduce its dependence on the oil and gas sector. This is expected to drive growth in other sectors, including healthcare, which is expected to benefit the Anti-Hypertensive Drugs market as well. Additionally, the country has a relatively young population, which is expected to drive demand for healthcare services in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
